UroGen Pharma URGN Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Net margin | -94.8%+45.0pp | -139.8%+30.8pp | -170.6%-6.1pp | -164.4%-13.8pp | -150.7%-10.3pp | |
| Efficiency | ||||||
| Asset turnover | 0.6×+0.1× | 0.5×+0.1× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Liquidity | ||||||
| Current ratio | 4.7×+0.7× | 4×0.0× | 4×-0.2× | 4.1×-1.5× | 5.6×-0.4× | |
| Valuation | ||||||
| Market capitalization | $875.31M-20.2% | $1.1B+18.8% | $922.97M+45.2% | $635.82M+24.7% | $509.8M+13.4% | |
| Price / sales | 6.2×-3.8× | 10×+0.4× | 9.6×+2.8× | 6.7×+1.2× | 5.5×+0.6× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are UroGen Pharma's profit margins?
- UroGen Pharma (URGN) runs a 89.7% gross margin and a -329.7% operating margin, with a -94.8% net margin.
- Where do UroGen Pharma's ratios come from?
- Every ratio is computed from UroGen Pharma's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.